Brought to you by 
Series C brings in $41.2mm for GlobeImmune
27 Sep 2007
Executive Summary
GlobeImmune (immunotherapeutics for cancer and infectious diseases) raised $41.2mm through a private placement of Series C preferred stock. New investor Wexford Capital led the round and was joined by other first-time buyers Celgene, Mellon Family Investment, Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, and WRF Capital. Existing backers also participated, including HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica Venture Partners, Adams Street Partners, Biogen Idec, Pac-Link Bioventures, China Investment and Development, Yasuda Enterprise Development, Partners Healthcare, and GC&H Investments.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $41.2mm for GlobeImmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice